Our unique GLUETAC R&D platform utilizes a proprietary E3 ligase ligand library with a diverse set of linkers and protein of interest binders to construct GLUETAC degraders library in a high-throughput way. The GLUETAC degraders developed from this platform can degrade target proteins with high selectivity and high oral bioavailability. The degraders are dedicated to solving the problem of refractory or resistance in the fields of solid tumors and autoimmune diseases, in order to bring clinical benefits to patients.

1. How to Choose a GLUETAC Target With “Wisdom” ?

2. What Makes Our GLUETAC Design More Precise and Efficacious?

3. Advantages of GLUETAC Medicinal Chemistry Platform

• Our design addresses “Wisdom” targets suitable for GLUETAC
• High throughput generating of GLUETAC library by merging Glue library
• Designed PRTOACs reduce off-target concerns

4. What Have We Done Successfully and How About Our Next Step in GLUETAC